Objectives: To determine if tedizolid is effective for pulmonary Mycobacterium avium complex (MAC) disease, and to use pharmacokinetics/pharmacodynamics to design optimal doses.
Introduction
We have identified linezolid as highly effective in the treatment of pulmonary infection caused by Mycobacterium avium complex (MAC), achieving at least 1.0 log 10 cfu/mL kill in ,7 days in the hollow-fibre system model of MAC (HFS-MAC), a level that we designated bactericidal, which was better than currently used drugs. [1] [2] [3] This effect was better than we have seen with either macrolides or ethambutol. [1] [2] [3] However, doses that could achieve the exposures associated with such efficacy were 1800 mg/day, which is high and in long-duration therapy is likely to be associated with high rates of toxicity. Tedizolid is an interesting congener of linezolid: it has 2-to 4-fold more potent in vitro activity against a variety of Grampositive organisms such as Staphylococcus aureus and streptococci associated with skin and soft tissue infections (SSTIs) and pneumonia. [4] [5] [6] [7] It has been shown to be non-inferior to linezolid in efficacy in the treatment of SSTIs when administered for half the duration and was associated with decreased incidence of adverse events effects in patients. [4] [5] [6] [7] Significantly, tedizolid's penetration into lung epithelial lining fluid (ELF) and alveolar macrophages is higher than that of linezolid. 8, 9 The mean tedizolid 0-24 h area under the concentration-time curve (AUC 0-24 ) ELF-to-serum and alveolar macrophage-to-serum penetration ratios (non-protein bound or free) were 40 and 20, respectively, higher than linezolid. 8, 9 In the US FDA docket, tedizolid MIC values reported against MAC were 0.06-2 mg/L, which was lower than the 0.5-8 mg/L for linezolid. 10 These differences in MIC and penetration suggest that much higher lung AUC 0-24 /MIC ratios could be achieved with tedizolid, and at lower rates of adverse events, than with linezolid. On the other hand, tedizolid has a protein binding of 86% compared with 31% for linezolid, a potential drawback. 9, 11 Here, we used the HFS-MAC to mimic human concentration-time profiles of tedizolid and identified the exposure associated with bactericidal effect, which we used to design optimal tedizolid doses.
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Materials and methods
Bacterial strain, chemicals and hollow-fibre cartridges Mycobacterium avium subsp. hominissuis (ATCC 700898) was purchased from ATCC (Manassas, VA, USA). Stock and propagation of cultures was as described previously.
1,2,12,13 THP-1 macrophages (TIB-202) were purchased from the ATCC. Tedizolid (active moiety) powder was synthesized for us by BOC Sciences (NY, USA). Hollow-fibre cartridges were purchased from FiberCell (Frederick, MD, USA).
Determination of MICs
Tedizolid MICs were determined using two methods. The first was broth macrodilution using Middlebrook 7H9 broth, as described previously for linezolid. 1 The tedizolid concentrations used were 0, 0.625, 1.25, 2.5, 5.0, 10.0, 20.0 and 40.0 mg/L, in triplicate. This experiment was performed twice. The second method employed the BACTEC TM MGIT TM 960 Mycobacterial Detection System (MGIT) system (BD, Becton Dickinson, Franklin Lakes, NJ, USA). MAC was grown into the logarithmic growth phase (log-phase growth) to an optical density (OD) of 0.08 at a wavelength of 600 nm. This was then diluted to achieve a bacterial density of 10 5 cfu/mL, of which 500 lL was inoculated into MGIT tubes, together with 0.8 mL of OADC supplement. The MGIT tube broth had been supplemented with tedizolid to make final concentrations of 0, 0.625, 1.25, 2.5, 5.0, 10.0, 20.0 and 40.0 mg/L. The MAC and tedizolid were co-incubated in the MGIT machine until growth detection. The lowest concentration of tedizolid that prevented the drug-containing tube from fluorescing within 2 days of the drug-free tube or control was defined as the MIC.
Infection of THP-1 cells with MAC and incubation with tedizolid
THP-1 cells were infected with MAC, then washed, as described previously. 1 We then co-incubated the infected THP-1 cells with tedizolid to make final concentrations of 0, 0.075, 0.15, 0.3, 0.6, 1.25, 2.5 and 5.0 mg/L, in 12-well plates, in triplicate. Cultures in RPMI 1640 and 10% FBS (RPMI/FBS) were incubated at 37 C and 5% CO 2 for 7 days. The drug was washed off, the THP-1 cells ruptured, and the cultures were then spread on agar and incubated for a further 14 days for colony counts.
Exposure-effect studies in the pulmonary HFS-MAC model
The details of the HFS-MAC model and its construction have been described previously. 2, 12, 13 We inoculated 20 mL of non-activated MAC-infected THP-1 cells into the external compartment of each of eight HFS that were preconditioned with RPMI/FBS and maintained in incubators at 37 C for at least 72 h. We mimicked the free-drug tedizolid concentration-time profiles encountered in human lungs. 9, 14 Tedizolid was administered via computer-programmed syringe pumps into an infusion port of the central compartment. Each HFS-MAC was dosed with once-daily tedizolid to achieve AUC 0-24 exposures of 0, 16, 23, 28, 30, 40, 45 and 50 mgÁh/L. The treatment duration was 28 days. Fresh RPMI/FBS was pumped into and out of the HFS-MAC at predefined rates to simulate the tedizolid half-life of 13 h encountered in adults, including in the lungs. 9, 14 We sampled the central compartments of each HFS-MAC at 1, 5, 8, 10, 13, 18 and 23 h after the first dose in order to confirm that the intended concentration-time profiles had been achieved. In order to quantify the number of THP-1 cells and bacterial burden, we sampled HFS-MAC peripheral compartments on days 0, 4, 7, 14, 21 and 28 of treatment. THP-1 cells were ruptured and contents cultured on agar at 37 C under 5% CO 2 for 14 days, for colony counts.
Tedizolid drug assay
Tedizolid concentrations in samples collected from the central compartment were analysed by liquid chromatography tandem-mass spectrometry in positive ion mode. For this assay, tedizolid and linezolid-D3 (internal standard) were purchased from Toronto Research Chemicals (Toronto, Canada) and CDN Isotopes (Pointe-Claire, Quebec, Canada), respectively.
Calibrator, controls and internal standard were included in each analytical run for quantification. Stock solutions of tedizolid and internal standard were prepared in 80:20 methanol:water at a concentration of 1 mg/mL and stored at # 20 C. A seven-point calibration curve was prepared by diluting tedizolid stock solution in drug-free medium (0.1, 0.4, 2, 4, 10, 20, 40 mg/L). Quality-control samples were prepared by spiking media with stock standards for two levels of controls. Samples were prepared in 96-well microtitre plates by the addition of 10 lL of calibrator, quality controls or sample to 190 lL 0.1% formic acid in water containing 1 mg/L internal standard followed by vortexing. Chromatographic separation was achieved on an Acquity UPLC HSS T31.8 lm 50%2.1 mm analytical column (Waters, MA, USA) maintained at 30 C at a flow of 0.2 mL/min with a binary gradient with a total run time of 6 min. The observed ions (m/z) values of the fragment ions were tedizolid (m/z 371.14 ! 343.18) and internal standard, linezolid-D3 (m/z 341.2 ! 297.11). Sample injection and separation was performed by an Acquity UPLC interfaced with a Xevo TQ mass spectrometer (Waters). All data were collected using MassLynx version 4.1 SCN810. The limit of quantification for this assay was 0.1 mg/L. The between-day and within-day percentage coefficient of variation (%CV) was 6% and 12%, respectively.
Pharmacokinetic and pharmacokinetic/ pharmacodynamic analysis
Pharmacokinetic analysis was performed using ADAPT 5 software. 15 We examined both one-compartment and two-compartment models, and chose the best model based on the Akaike Information Criterion (AIC), the Bayesian information criterion (BIC) and parsimony. The pharmacokinetic parameters identified were used to calculate the AUC 0-24 achieved in each HFS-MAC unit. The calculated AUC 0-24 /MIC for each system was then used in an inhibitory sigmoid maximal kill (E max ) model for each day of sampling. We used this relationship to calculate the EC 80 (i.e. exposure that gives 80% of E max ), the exposure associated with bacteriostasis (no change in cfu/mL compared with day 0), 1.0 log 10 cfu/mL decline compared with day 0 (bactericidal effect), and 2.0 log 10 cfu/mL decline from start of therapy.
Monte Carlo simulations
We performed 10000 patient Monte Carlo simulations to identify how well doses of 100, 200 and 300 mg would achieve, or exceed, the tedizolid AUC 0-24 /MIC associated with bacteriostasis, EC 80 , bactericidal effect and 2.0 log 10 cfu/mL kill. For the domain of input, we used population pharmacokinetic analyses published by Flanagan et al. 16 The pharmacokinetics are linear across a dose range of 100-400 mg/day, with the population pharmacokinetic parameter estimates shown in Table 1 . Bioavailability was set at 90%, and protein binding at 86%. For the lung penetration indices, we used the free drug AUC 0-24 penetration ratio of 20 identified for alveolar macrophages by Housman et al. 9 We utilized the MIC distribution of VeraCabrera et al., 10, 17 and the ones used in the FDA package insert.
Results
The tedizolid MIC by the broth macrodilution method was 1.25 mg/L, while that using MGIT was 0.625 mg/L, and thus within one-tube dilution. This is consistent with the findings between MGIT and broth methods for Mycobacterium tuberculosis, with MGIT-based MICs 1-2 dilutions lower than broth macrodilutionbased MICs. Each result was obtained twice. We adopted the value of 1.25 mg/L, based on the broth macrodilution method. Results of the concentration-effect study in 12-well plates are shown in Figure 1 after 7 days of incubation. The E max was 1.57+0.14 log 10 cfu/mL, while the EC 50 was 4.52+0.84 % MIC (r 2 " 0.97).
Tedizolid for pulmonary MAC JAC ii31
In the HFS-MAC the tedizolid concentrations based on both AIC scores (#1793 versus #1713) and BIC scores (#1770 versus #1699) were better described by a two-compartment model rather than a one-compartment model, but based on parsimony (Occam's razor) there was hardly any significant change in total clearance and volume; thus we chose the one-compartment model for reporting. In that model, the tedizolid clearance was 0.017 L/h, while the volume was 0.331 L, which translates to a half-life of 13.8 h.
The time-kill plots for microbial kill in each HFS-MAC are shown in Figure 2 . The figure shows that the maximal kill below stasis was 2.07 log 10 cfu/mL. This was encountered on day 14. The maximal microbial kill of . 2.0 log 10 cfu/mL was achieved by treatment with an AUC 0-24 /MIC of 37.50. Figure 2 also shows that at this exposure, the bacterial burden persisted below 1.0 log 10 cfu/mL kill for 28 days, at which point the experiment was terminated.
Inhibitory sigmoid E max modelling for each day of sampling revealed the curves shown in Figure 3 . The lowest AIC score was on day 14, which was also the sampling day with the deepest level of kill compared with baseline (Figures 2 and 3 The exposure associated with bacteriostasis, just holding the bacterial burden constant without growth or decline, was an AUC 0-24 /MIC of 17.15. The EC 80 was an AUC 0-24 /MIC of 21.71. The exposure associated with 1.0 log 10 cfu/mL kill or bactericidal effect was an AUC 0-24 /MIC ratio of 23.46, virtually the same as the EC 80 . The AUC 0-24 /MIC associated with 2.0 log 10 cfu/mL kill was 37.5.
We also monitored the MAC bacterial burden using time-topositivity (TTP) in the MGIT, a potentially more sensitive assay at low bacterial burdens that also provides answers faster than enumeration of colony counts. Figure 4 shows results for sigmoid E max model regressions on days 14-28: earlier sampling timepoints showed no model convergence. Interestingly, the EC 50 on day 14 was virtually the same as that identified with the cfu/mL Deshpande et al.
ii32 method, and was an AUC 0-24 /MIC ratio of 17.30 with overlapping confidence bounds (r 2 " 0.88). This means that TTP as measure of MAC bacterial burden can be used to monitor therapy in the future, with exposure-effect regression models similar to those for cfu/mL measurement.
In the Monte Carlo simulation experiments, the population pharmacokinetic parameter estimates identified for the 10000 simulated patients were as shown in Table 1 . Table 1 shows that the pharmacokinetic parameter estimates mirrored those in the domain of input well, thereby internally validating that the Monte Carlo experiments had been successful. The tedizolid halflife identified in the simulated subjects was 13.04 h. The target attainment probability for the bacteriostasis target was as shown in Figure 5 (a). Based on the MIC distribution for tedizolid in the FDA docket, all doses, including 200 mg/day, achieved close to 100% target attainment, including the highest MIC identified for MAC for the bacteriostasis target. For the bactericidal effect target (1.0 log 10 cfu/mL kill or EC 80 ), the cumulative fraction of response was .90% for the standard dose of 200 mg/day (Figure 5b) . The 2.0 log 10 cfu/mL kill target shown in Figure 5 (c) is more stringent, and the dose of 200 mg/day had a cumulative fraction of response of 73%, while 300 mg/day was 80%, and 400 mg/day was 97%. However, for an MIC of 1.0 mg/L or below, which is our proposed susceptibility breakpoint, the cumulative fraction of response was 97% for 200 mg/day.
Discussion
Our main finding is to demonstrate, for the first time, an antibiotic that can achieve bactericidal activity against MAC below stasis of 2 log 10 cfu/mL at exposures likely to be clinically achievable. This level of antibiotic bactericidal activity has not been previously seen in the HFS-MAC model, except with thioridazine exposures that would be fatal to patients. 13 Even then, the thioridazine effect was biphasic and was accompanied by rapid emergence of thioridazine resistance within 14 days. Ethambutol and azithromycin currently constitute the backbone of the currently recommended regimen for MAC. 18 However, in the same HFS-MAC model ethambutol achieved an E max of 0.79 log 10 cfu/mL compared with 3.78 log 10 cfu/mL with tedizolid; however, the bacterial burden at the ethambutol E max was actually higher than on day 0, which is worse than bacteriostatic. 2 Similarly, for azithromycin in the HFS-MAC, the E max was 2.11 log 10 cfu/mL, but a meagre 0.6 log 10 cfu/mL below stasis, which was quickly abrogated by emergence of resistance to the monotherapy. 19 Even then, using Monte Carlo simulations we have shown that the standard azithromycin dose of 500 mg/day would achieve that meagre kill below stasis in only about 7% of patients. 3 In the accompanying papers, we show that the combination of azithromycin and ethambutol still killed less than what we identified here with tedizolid alone; triple standard therapy with rifabutin was just a little over 1.0 log 10 cfu/mL kill compared with day 0 with 28 days of daily therapy. 20, 21 Compared with linezolid, tedizolid surpassed the 1 log 10 cfu/mL kill seen with linezolid, and did not show rebound. 1 The efficacy suggests that tedizolid could form the best building block for a short-course chemotherapy regimen for pulmonary MAC.
Another finding is that compared with the first 14 days, there is reduced magnitude of kill in the second half of the study with flattening of the kill curves. There are two possible explanations. This could be due to emergence of tedizolid resistance on monotherapy, emphasizing the need for combination therapy. However, we failed to capture tedizolid-resistant isolates, which suggests that persistence within macrophages might play a role. A second explanation could be a switch of the MAC to non-replicating antibiotic-tolerant phenotype with increased duration of therapy. This needs further study.
A third finding is that Monte Carlo simulations identified the current standard regimen for tedizolid of 200 mg administered once daily as the optimal dose for achieving both bacteriostasis and a bactericidal effect. Indeed, the dose of 200 mg/day would also . Time-to-positivity (TTP) as an indicator of response to treatment in the hollow-fibre system. TTP is inversely proportional to bacterial burden, thus the larger the bacterial burden, the shorter the TTP. There was an increase in TTP with progression of treatment duration until a maximal TTP noted on day 14. This reflects the cfu/mL readout well. In this case, given the inverse relationship between cfu/mL and TTP, we used sigmoid E max models (not an inhibitory one) to calculate the EC 50 , whose 95% CI overlapped with those derived using cfu/mL. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Tedizolid for pulmonary MAC JAC achieve the 2 log 10 cfu/mL kill target up to MICs of 1 mg/L, our recommended susceptibility breakpoint; the use of doses of 300-400 mg/day is better above this MIC. Thus, for tedizolidsusceptible isolates, 200 mg/day would be the optimal dose, with a zone of dose-dependent killing at MICs of 2 mg/L. This is fortunate, since this tedizolid dose of 200 mg/day has been compared with the standard linezolid 1200 mg dose for toxicity in several studies. In short-duration studies, Flanagan et al. 22 predicted treatment-emergent adverse event probabilities of 0.15 and 0.16 in European and South African patients treated with 200 mg/day tedizolid, and probabilities of 0.22-0.24 at a dose of 400 mg; probabilities of adverse events were higher in Americans. In terms of mitochondrial inhibition, the 200 mg/day tedizolid dose would stay above the concentration mediating clinically significant mitochondrial inhibition in only 16% of patients compared with 62% of patients receiving 600 mg linezolid twice a day. 23 With more prolonged therapy substantially abnormal haematological parameters were only identified with 600 mg linezolid twice a day and 400 mg tedizolid once a day, but not with 200 or 300 mg tedizolid per day. 24 Thus, the 200 mg tedizolid dose we identified as optimal is likely to be far less toxic than the linezolid dose of 1800 mg a day we identified as optimal, with an effect that exceeds that of linezolid.
Lastly, TTP in the MGIT has been used as a predictor of bacterial burden for tuberculosis and in early bactericidal activity studies of antituberculosis agents. 25, 26 In this study, we employed TTP of MAC as a method for monitoring bacterial burden. Given that the method identified a virtually identical EC 50 compared with the gold standard of colony counts, it could serve as a more rapid readout for MAC pharmacokinetics/pharmacodynamics studies.
Our study has, however, some limitations. First, we used a single strain of MAC for the entire study. Examination of wild strains in addition to a standard strain would give added value. However, we took the MIC distribution into account when we performed the Monte Carlo simulations. Second, we failed to capture the tedizolid-resistant subpopulation, similar to the problems with linezolid resistance. This is likely due to the limitation of our drug resistance assays for oxazolidinones. We plan to use liquid media to capture this effect in the future. Third, in our simulations, we utilized the drug penetration ratios into alveolar macrophages, and not ELF, as we normally do. Since the tedizolid penetration ratios into ELF are two times higher than into macrophages, tedizolid doses would have performed even better in terms of the optimal dose, and would achieve 2.0 log 10 cfu/mL kill even at MICs of 4 mg/L with a 200 mg/day dose. Thus, we may have been too conservative in our calls. Finally, the doses we identified will need to be tested in clinical trials for final validation.
In summary, we show that tedizolid is associated with extensive microbial kill of MAC and, given its penetration into the lungs, is an ideal drug for pulmonary MAC. Moreover, we identified the susceptibility breakpoint for tedizolid of 1 mg/L at the standard dose of 200 mg/day, above which patients are likely to fail therapy; 2 mg/L was a susceptible-dose-dependent breakpoint. These results mean that tedizolid should be used to form the background regimen for shorter-duration therapy for pulmonary infection with MAC. Figure 5 . Target attainment probabilities for bacteriostasis, bactericidal effect and 2 log 10 cfu/mL kill. (a) Target attainment probability (TAP) for the bacteriostasis target exposure indicates that all doses examined achieved 100% TAP up to 2 mg/L, the highest MIC in the distribution in the FDA docket. (b) TAP for bactericidal effect (1 log 10 cfu/mL kill) as well as EC 80 targets indicates high TAP for all doses, except above the MIC of 1.0 mg/L with the 200 mg/day dose. That MIC is the proposed susceptibility breakpoint for MAC. (c) TAP for the 2 log 10 cfu/mL kill exposure target shows good performance by the 200 mg dose, except above the proposed susceptibility breakpoint; however, 400 mg/day would work above this MIC, but not at an MIC !4 mg/L, which means that the MIC of 2 mg/L is a susceptible-dose-dependent breakpoint.
